Literature DB >> 3946535

Effect of adding betaxolol to dipivefrin therapy.

R N Weinreb, R Ritch, F H Kushner.   

Abstract

We evaluated the safety and effectiveness of adding topically administered betaxolol 0.5% twice daily in 39 patients with ocular hypertension or primary open-angle glaucoma already being treated with dipivefrin 0.1% twice daily. The addition of the betaxolol significantly decreased (P less than .01) the mean intraocular pressure after two weeks (2.82 mm Hg) and four weeks (3.63 mm Hg). There were no significant changes in pulse rate, mean arterial pressure, or pupil diameter. The administration of betaxolol to patients already receiving dipivefrin appears to be clinically useful.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3946535     DOI: 10.1016/0002-9394(86)90594-5

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

Review 1.  Pharmacological therapy for glaucoma: a review.

Authors:  P F Hoyng; L M van Beek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

2.  The efficacy of the combination of l-moprolol and dipivefrin in reducing the intraocular pressure in primary open-angle glaucoma or in ocular hypertension.

Authors:  L Rossetti; P Barbieri; P Velati; E Bujtar; N Orzalesi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-11       Impact factor: 3.117

Review 3.  Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension.

Authors:  M M Buckley; K L Goa; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

Review 4.  Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.

Authors:  A M Brooks; W E Gillies
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

5.  Effects of topical timolol (0.5%) and betaxolol (0.5%) on corneal sensitivity.

Authors:  S S Weissman; P A Asbell
Journal:  Br J Ophthalmol       Date:  1990-07       Impact factor: 4.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.